Injective (INJ) is currently trading at $4.61, reflecting a 24-hour change of 2.82%. The asset has experienced a daily price range of $4.44 to $4.64, indicating a relatively stable trading environment with a daily range of just 0.2%.

The trading volume stands at approximately 33.73 million, which constitutes 7.31% of its market cap, suggesting robust liquidity. Moving averages indicate a bullish short-term trend with the 8 SMA at $4.53 (+1.69%) and the 13 SMA at $4.51 (+2.23%), while the longer-term 144 SMA shows a slight bearish trend at $4.65 (-0.79%).

The 1-hour RSI is at 69, indicating that INJ is approaching overbought territory, while the 7-day RSI at 53 suggests a neutral stance over a longer period. In contrast, both the 14-day and 30-day price changes are negative, showing declines of approximately 13.82% and 19.01%, respectively, which may indicate underlying bearish sentiment.

Despite the recent uptick in price, the 7-day price change of -0.09% and the longer-term declines suggest that the market is still in a correction phase. The all-time high for INJ was $52.62, achieved in March 2024, which establishes a significant distance from the current price, indicating substantial potential upside but also heightened risk.

Given the short-term bullish signals juxtaposed with longer-term bearish trends and a high RSI suggesting overbought conditions, a cautious approach is warranted. Therefore, the rating for Injective (INJ) is a Hold, as it may be prudent to wait for a clearer bullish reversal or further confirmation of sustained upward momentum before initiating new positions.